18 - Empagliflozin Is Associated With Increased Plasma Lipid Metabolites in Type 1 Diabetes
Hongyan Liu(Jinan City People's Hospital), David Z. Cherney, Leif Erik Lovblom(Mount Sinai Hospital), Hongping Ye(The University of Texas at San Antonio Health Science Center), Bruce A. Perkins(Sinai Health System), Yuliya Lytvyn(University Health Network), Kumar Sharma(The University of Texas at San Antonio Health Science Center), Daniel Montemayor(The University of Texas at San Antonio Health Science Center), Daniel Scarr(Mount Sinai Hospital)
Cited by 0
Related Papers
The NASA Twins Study: A multidimensional analysis of a year-long human spaceflight
|Science|2019|1.1k
Metabolomics Reveals Signature of Mitochondrial Dysfunction in Diabetic Kidney Disease
|Journal of the American Society of Nephrology|2013|578
Sodium Glucose Cotransporter-2 Inhibition in Heart Failure
|Circulation|2017|470
Sex-Related Disparities in CKD Progression
|Journal of the American Society of Nephrology|2018|299
Rationale and design of the Kidney Precision Medicine Project
|Kidney International|2021|187